Trial Profile
First-phase viral decay rates in treatment-naive subjects initiating treatment with raltegravir (RAL) and emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF): A pilot study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 28 Nov 2015 Results from two studies (MK0518-004 and ACTG-A5248) regarding early viral kinetics were published in the AIDS.
- 07 Nov 2012 Actual initiation date changed from Jun 2008 to May 2008 as reported by ClinicalTrials.gov.
- 25 Apr 2012 Actual patient number changed from 39 to 40 as reported by ClinicalTrials.gov.